Berkane N, Cocheton J J, Brehier D, Merviel P, Wolf C, Lefèvre G, Uzan S
Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Tenon, Paris, France.
Acta Obstet Gynecol Scand. 2000 Nov;79(11):941-6.
We studied the clinical and biological effects and safety of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy (ICP).
All cases of ICP treated with ursodeoxycholic acid in our department from January 1st, 1991 to May 31st, 1997 were reviewed.
Forty-three patients had ICP, of whom 19 received ursodeoxycholic acid. The first symptoms appeared after a mean of 29.7 weeks of pregnancy (WP). Treatment was started after a mean of 32 WP, and lasted a mean of 28.5 days. Fourteen patients showed a clinical improvement on UDCA, and 11 showed a biological improvement. Two had a biological deterioration with increased liver enzyme concentrations.
Ursodeoxycholic acid appears to be an effective treatment for ICP, but further studies are needed to confirm its safety in pregnancy.
我们研究了熊去氧胆酸对妊娠肝内胆汁淤积症（ICP）患者的临床、生物学效应及安全性。
回顾了1991年1月1日至1997年5月31日在我科接受熊去氧胆酸治疗的所有ICP病例。
43例患者患有ICP，其中19例接受了熊去氧胆酸治疗。首次症状出现在平均妊娠29.7周后。治疗开始于平均妊娠32周，持续平均28.5天。14例患者使用熊去氧胆酸后临床症状改善，11例生物学指标改善。2例患者肝酶浓度升高，生物学指标恶化。
熊去氧胆酸似乎是治疗ICP的有效药物，但需要进一步研究以证实其在妊娠期间的安全性。
